AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$VNRX

VOLITIONRX LTD (VNRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 10, 2026, Singapore Volition Pte. Limited (“Singapore Volition”), a wholly-owned subsidiary of VolitionRx Limit

Original reporting
SEC EDGAR 8-K
Published Nov 12, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$VNRX
Neutral
medium confidence
Mentioned
$VNRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VNRXNeutralLow
01

Why it matters

The filing provides the first public details of the salary reduction and associated RSU grant adjustments.

02

Market read

The disclosure is a primary source filing but involves modest financial impact, resulting in low trading relevance.

03

What to watch

Potential upcoming licensing deal that could restore salary levels and boost cash flow.

Relevance 6/10Novelty 4/10Timing: filing date November 12, 2026

Background

VolitionRx Ltd (VNRX) filed a Form 8‑K reporting changes to its CEO's compensation as part of ongoing cost‑reduction measures.

Company-level read

Ticker impact

$VNRXNeutralMedium confidence
Context

SEC 8‑K filing discloses a further temporary salary reduction for CEO Cameron Reynolds and related compensation changes.

Expected impact

likely modest downside as investors view reduced executive compensation as a sign of cash constraints

Evidence & confidence

Compensation adjustments are material for the company but involve small cash flow effects and no new equity issuance.

Market effects

Sector

Limited; reflects broader cost‑control trends in biotech micro‑caps.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The salary cut could be a prelude to a larger restructuring that may improve long‑term margins.

Key entities

  • Executive
    Cameron Reynolds

    Chief Executive Officer and President of VolitionRx Ltd.

Read at source← All news

Related articles

$VNRXMed

VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, November 12, 2026 /PRNewswire/ -- Vo

SEC EDGAR 8-K
$VNRXMedAI 8/10

Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down

VolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.

rttnews.com
$VNRXLow

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit

SEC EDGAR 8-K
$VNRXMed

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

prnewswire.com
$NVDAMed

Colette Kress Has Been Named Interim Chief of Nvidia. But There’s Another Executive Favored to Replace Jensen Huang

Nvidia's CFO Colette Kress has been named interim CEO following Jensen Huang's resignation. Prediction markets favor Ian Buck, a 22-year Nvidia veteran and creator of CUDA, as the likely permanent replacement. Buck's potential appointment is seen as a way to maintain Nvidia's innovation and technological edge, though his ability to manage commercial and geopolitical challenges may face scrutiny.

finance.yahoo.com